Qualitative and quantitative insights were obtained by interviewing supply-side and demand-side stakeholders during the primary research process. The supply-side sources consist of CEOs, VPs of Product Development, regulatory affairs chiefs, eye bank directors, and commercial directors from ophthalmic device OEMs, artificial cornea manufacturers, and corneal tissue processors. Demand-side sources included procurement leads from tertiary eye hospitals, specialty eye clinics, and ambulatory surgical centers, as well as corneal surgeons, ophthalmology department leaders, and eye bank medical directors. Primary research has confirmed the product pipeline timelines for bioengineered corneas and cell therapies, and has gathered insights on surgical adoption patterns, tissue pricing strategies, and reimbursement dynamics across public and private healthcare systems. This research has validated market segmentation across procedure types (penetrating keratoplasty, Descemet Membrane Endothelial Keratoplasty, Descemet Stripping Automated Endothelial Keratoplasty, anterior lamellar keratoplasty), donor sources (deceased donor, living donor), techniques (surgical, minimally invasive, robotic-assisted), and product types (corneal grafts, preservation solutions, instruments).
Primary Respondent Breakdown:
By Company Tier: Tier 1 (38%), Tier